Leukogene Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Leukogene Therapeutics is a private, preclinical-stage biotech company spun out from the Medical University of South Carolina (MUSC) and headquartered in Charleston, SC, with a presence in San Diego. The company is pioneering a novel immunotherapy approach that targets MHC class II to activate a coordinated, tumor antigen-specific immune response, aiming to overcome limitations of existing therapies. Its lead programs are in acute myeloid leukemia (AML) and pancreatic ductal adenocarcinoma (PDAC), with demonstrated preclinical proof of concept. Leukogene is backed by the National Cancer Institute (NCI) and SCRA SC Launch.

Oncology

Technology Platform

M2T™ (MHCII-Targeted) immunotherapy platform: recombinant proteins that conjugate tumor-associated antigens (TAAs) to a protein that binds tightly to MHC class II on antigen-presenting cells. This hijacks the MHCII pathway to trigger a coordinated, tumor antigen-specific immune response involving CD4+ and CD8+ T cells, designed to break tolerance and work independently of HLA polymorphisms.

Opportunities

The company targets a large, underserved market of patients with immunologically 'cold' tumors like pancreatic cancer and AML, which are poorly addressed by current immunotherapies.

Its platform's potential for combination therapy with existing modalities (e.g., checkpoint inhibitors) could significantly expand efficacy and market reach.

The MHCII-targeting approach is novel and could offer a first-in-class mechanism with broad applicability across multiple solid and hematologic cancers.

Risk Factors

The novel M2T™ platform carries high biological risk, as its complex mechanism of action is unproven in humans and may face safety challenges like autoimmunity.

As a preclinical, private company, it faces significant financing risk and must raise substantial capital to reach the clinic.

The competitive landscape in cancer immunotherapy is intensely crowded with well-funded players pursuing diverse mechanisms.

Competitive Landscape

Leukogene competes in the broad cancer immunotherapy space against giants like Merck, Bristol Myers Squibb, and Roche, as well as numerous biotechs. Its direct competitors are companies developing therapies that engage CD4+ T cells or target antigen presentation pathways, such as those focusing on dendritic cell vaccines or MHC-targeting bispecifics. Its differentiation lies in its specific focus on engineering proteins to directly hijack the MHCII pathway for coordinated immune activation, a niche approach with few known clinical-stage analogues.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →